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Abstract: Background: The incidence and mortality of renal cell carcinoma (RCC) after kidney
transplantation (KTx) remain unclear. This study’s aims were (1) to investigate the pooled
incidence/incidence trends, and (2) to assess the mortality/mortality trends in KTx patients with
RCC. Methods: A literature search was conducted using the MEDLINE, EMBASE and Cochrane
databases from inception through October 2018. Studies that reported the incidence or mortality of
RCC among kidney transplant recipients were included. The pooled incidence and 95% CI were
calculated using a random-effect model. The protocol for this meta-analysis is registered with
PROSPERO; no. CRD42018108994. Results: A total of 22 observational studies with a total of
320,190 KTx patients were enrolled. Overall, the pooled estimated incidence of RCC after KTx was
0.7% (95% CI: 0.5–0.8%, I2 = 93%). While the pooled estimated incidence of de novo RCC in the native
kidney was 0.7% (95% CI: 0.6–0.9%, I2 = 88%), the pooled estimated incidence of RCC in the allograft
kidney was 0.2% (95% CI: 0.1–0.4%, I2 = 64%). The pooled estimated mortality rate in KTx recipients
with RCC was 15.0% (95% CI: 7.4–28.1%, I2 = 80%) at a mean follow-up time of 42 months after
RCC diagnosis. While meta-regression analysis showed a significant negative correlation between
year of study and incidence of de novo RCC post-KTx (slopes = −0.05, p = 0.01), there were no
significant correlations between the year of study and mortality of patients with RCC (p = 0.50).
Egger’s regression asymmetry test was performed and showed no publication bias in all analyses.
Conclusions: The overall estimated incidence of RCC after KTX was 0.7%. Although there has been a
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potential decrease in the incidence of RCC post-KTx, mortality in KTx patients with RCC has not
decreased over time.
Keywords: malignancy; post-transplant malignancy; renal cell carcinoma; meta-analysis; kidney
transplantation; transplantation; systematic reviews
1. Introduction
Kidney transplantation (KTx) is the renal replacement therapy of choice for the majority of
patients with end-stage renal disease (ESRD) and it significantly improves survival and quality of
life [1,2]. The long-term mortality rate is 48% to 82% lower in KTx recipients when compared to ESRD
patients on the transplant waitlist [2,3]. However, due to immunosuppression, KTx patients are at
a two-fold increased risk of developing malignancy in comparison to the general population [4–6].
Malignancies are among the top three leading causes of death in KTx recipients, following infection
and cardiovascular complications [6].
Studies have demonstrated a higher incidence of renal cell carcinoma (RCC) among ESRD patients
(0.3%) than its reported incidence in the general population (approximately 0.005%) [7,8]. Thus,
the Clinical Practice Guidelines Committee of the American Society of Transplantation (AST) [9] has
recommended RCC screening for high-risk candidates, such as ESRD patients on dialysis for more
than 3 years [10]. Despite screening for RCC among KTx candidates, de novo RCC has been reported
among KTx patients in both native kidneys [11–18], and transplanted kidneys [17,19,20]. However,
the incidence and incidence trends of RCC among KTx patients remain unclear [11–42].
Thus, we performed a systematic review to (1) investigate the pooled incidence/incidence trends,
and (2) assess the mortality/mortality trends in KTx patients with RCC.
2. Methods
2.1. Search Strategy and Literature Review
The protocol for this systematic review is registered with PROSPERO (International Prospective
Register of Systematic Reviews; no. CRD42018108994). A systematic literature search of MEDLINE
(1946 to October 2018), EMBASE (1988 to October 2018), and the Cochrane Database of Systematic
Reviews (database inception to October 2018) was performed to assess (1) the pooled incidence/incidence
trends, and (2) to assess the mortality/mortality trends in KTx patients with RCC. The systematic
literature review was conducted independently by two investigators (C.T. and W.C) using a search
strategy that consolidated the terms “kidney cancer” OR “renal cell carcinoma” AND “kidney
transplantation” OR “renal transplantation” which is provided in the online Supplementary Data S1.
The database searches were limited to English language articles only. A manual search for conceivably
related studies using references of the included articles was also performed. This study was
conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
statement [43].
2.2. Selection Criteria
Eligible studies had to be clinical trials or observational studies (cohort, case-control, or
cross-sectional studies) that reported the incidence or mortality of RCC among adult KTx recipients
(age >/= 18 years old). Retrieved articles were individually reviewed for eligibility by two investigators
(A.C. and C.T.). Discrepancies were addressed and solved by mutual consensus. Inclusion was not
limited by the size of study.
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2.3. Data Abstraction
A structured data collecting form was used to obtain the following information from each study:
title, name of the first author, year of the study, publication year, country where the study was
conducted, RCC definition, incidence of RCC, and mortality in KTx patients with RCC.
2.4. Statistical Analysis
Analyses were performed utilizing the Comprehensive Meta-Analysis 3.3 software (Biostat Inc,
Englewood, NJ, USA). Adjusted point estimates from each study were consolidated by the generic
inverse variance approach of DerSimonian and Laird, which designated the weight of each study based
on its variance [44]. Given the possibility of between-study variance, we used a random-effect model
rather than a fixed-effect model. Forest plots were constructed to visually evaluate the incidence and
mortality of RCC among adult KTx recipients. Cochran’s Q test and I2 statistic were applied to determine
the between-study heterogeneity. A value of I2 of 0–25% represents insignificant heterogeneity, 26–50%
low heterogeneity, 51–75% moderate heterogeneity and 76–100% high heterogeneity [45]. The presence
of publication bias was assessed using the Egger test [46]. Funnel plots were created to evaluate for the
presence or absence of publication bias.
3. Results
A total of 7815 potentially eligible articles were identified using our search strategy. After the
exclusion of 7629 articles based on their title and abstract for clearly not fulfilling the inclusion criteria
on the basis of type of article, patient population, study design, or outcome of interest, and 81 due to
being duplicates, 105 articles were left for full-length review. Fifty-nine of them were excluded from
the full-length review as they did not report the outcome of interest. Twenty-one articles were case
reports and three articles were not in English. Thus, 22 cohort studies [11–20,23,28–36,38,39] with a
total of 320,190 KTx patients were enrolled. The literature retrieval, review, and selection process are
demonstrated in Figure 1. The characteristics of the included studies are presented in Table 1.
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Table 1. Main characteristics of studies included in the meta-analysis of incidence and mortality of renal cell carcinoma (RCC) after kidney transplantation
(KTx) [11–20,23,28–36,38,39].
Study Year Type ofStudy
Number of
Patients Incidence of RCC
Follow-Up Time after
Transplant
Time from Transplant to
Cancer Diagnosis Mortality of RCC
Quality
Assessment
Hoshida et al. [11] 1997 Cohort 1744 15/1744 N/A N/A N/A S4 C0 O3
Agraharkar et al. [12] 2004 Cohort 1739 6/1739 Mean 6.1 years N/A N/A S4 C1 O3
Neuzillet et al. [13] 2004 Cohort 933 11/933 N/A Mean 70.9 ± 49.4(range 8–156) months
2/11 (1 died due to
cancer) S4 C0 O2
Moudouni et al. [14] 2006 Cohort 373 10/373 N/A
Mean 12.8 years
Median 127 in patients
treated with cyclosporine A
and 114 months in patients
not treated with
cyclosporine A
1/10 (1 died due to
cancer) S4 C0 O3
Ianhez et al. [39] 2007 Cohort 1375
10/1375
9 in native kidney
1 in allograft kidney
N/A N/A
3/10 (2 died due to
myocardial infarction and
one due to penile cancer)
S4 C0 O2
Schwarz et al. [38] 2007 Cohort 561
8/561
7 de novo in native
kidney
1 de novo in allograft
kidney
N/A 105.2 ± 62.39 months N/A S4C2O3
Tsai et al. [15] 2008 Cohort 3259
Touring group
15/215 kidney cancer
Domestic group
4/321 kidney cancer
Touring group
Mean 76.2 ± 48.1 months
Domestic group
Mean 81.5 ± 53.4 months
N/A N/A S4 C1 O3
Filocamo et al. [16] 2009 cohort 694 Native de novo10/694 N/A
61.8 months
(12–156 months)
3/10 (3 died due to cancer
other than RCC) S4 C1 O3
Leveridge et al. [17] 2010 cohort 3568 39/3568 native kidney8/3568 allograft kidney 6.6 years
Native 10.6 years
allograft 12.1 years
5 native died (not RCC
cause), 1 allograft died
due to cardiac cause
S4 C0 O3
Hwang et al. [18] 2011 Cohort 1695 7/1695 9.1 ± 6.9 years Mean 11.8 ± 6.0 years N/A S4 C0 O3
Lee et al. [28] 2011 Cohort 2757 21/2757 N/A Mean 119 (range 0–264)months N/A S4 C1 O2
Ploussard et al. [20] 2012 Cohort 2396 Allograft kidney12/2396 N/A Mean 13 (range 4–20) years 0/12 S4 C0 O3
Einollahi et al. [29] 2012 Cohort 12,525 6/12,525 N/A Median 16 months N/A S4 C0 O3
Gigante et al. [30] 2012 Cohort 213 N/A N/A Mean 91 ± 82 months 6/213 due to RCC S4 C0 O2
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Table 1. Cont.
Study Year Type ofStudy
Number of
Patients Incidence of RCC
Follow-Up Time after
Transplant
Time from Transplant to
Cancer Diagnosis Mortality of RCC
Quality
Assessment
Tillou et al. [19] 2012 Cohort 41,806 Allograft kidney79/41,806 N/A
Mean 131.7 (0.9–244)
months 4/79 S4 C0 O3
Cheung et al. [31] 2012 Cohort 4895 26/4895 N/A Median 4 (0.2–16.5) years N/A S4 C1 O3
Piselli et al. [32] 2013 Cohort 7217 31/7217 Median 5.2 years (2.9–7.8) N/A N/A S4 C1 O3
Ryosaka et al. [33] 2015 Cohort 202 N/A N/A N/A
Solid-type renal cell
carcinoma
2/17
Cystic-type renal cell
carcinoma
2/27
S4 C0 O3
Kalil et al. [34] 2015 Cohort 115,845
Primary kidney
transplant
514/109,224
Retransplant
43/6621
Mean
1st–4.6 years
2nd–3.7 years
3rd–2.9 years
4th–3.4 years
N/A N/A S4 C2 O3
Karami et al. [35] 2016 Cohort 116,208 683/116,208 Median 4.2 years (range0.003–23.1) N/A N/A S4 C0 O2
Takagi et al. [36] 2017 Cohort 42 N/A N/A Mean 86 ± 69 months 9/42 (5 died dueto cancer) S4 C0 O3
Cognard et al. [23] 2018 Cohort
143 with history
of
pre-transplant
kidney cancer
13/143 Mean 5.6 ± 3.2 years Mean 3 ± 2.3 years(range 45 days–7 years)
10/13 (9 died due
to cancer) S4 C0 O3
KTx, kidney transplantation; N/A, not available; RCC, renal cell carcinoma; S, C, O, selection, comparability, and outcome.
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3.1. Incidence of RCC after KTx
Eighteen studies provided data on the incidence of RCC after KTx [11–20,28,29,31,32,34,35].
Overall, the pooled estimated incidence of RCC after KTx was 0.7% (95% CI: 0.5–0.8%, I2 = 93%,
Figure 2). While the pooled estimated incidence of de novo RCC in the native kidney was 0.7% (95%
CI: 0.6–0.9%, I2 = 88%, Figure 3A), the pooled estimated incidence of RCC in the allograft kidney was
0.2% (95% CI: 0.1–0.4%, I2 = 64%, Figure 3B).
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Figure 2. Forest plots of the included studies [11–20,28,29,31,32,34,35,38,39] assessing incidence rates
of RCC after KTx. A diamond data marker represents the overall rate from each included study (square
data marker) and 95% confidence interval.
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Figure 3. Forest plots of the included studies [11–18,28,29,31,32,34,35,38,39] assessing incidence rates of
(A) de novo RCC in the native kidney and (B) RCC in the allograft kidney [17,19,20,38,39]. A diamond
data marker represents the overall rate from each included study (square data marker) and 95%
confidence interval.
J. Clin. Med. 2019, 8, 530 7 of 15
Meta-regression showed a significant negative correlation between year of study and incidence of
de novo RCC post-KTx (slopes = −0.05, p = 0.01, Figure 4).
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Figure 4. Meta-regression analyses showed a significant negative correlation between the year of
study and incidence of de novo RCC post-KTx (slopes = −0.05, p = 0.01). The solid line represents the
weighted regression line based on variance-weighted least squares. The inner and outer lines show the
95% confidence interval and prediction interval around the regression line. The circles indicate the log
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3.2. Mortality Rate in KTx Recipients with RCC
Eleven studies provided data the on mortality rate in KTx recipients with
RCC [13,14,16,17,19,20,23,30,33,36,39]. Overall, the pooled estimated mortality rate in KTx recipients
with RCC was 15.0% (95% CI: 7.4–28.1%, I2 = 80%, Figure 5) at a mean follow-up time of 42 months
after RCC diagnosis. The data on the incidence and mortality of recurrent RCC among KTx recipients
with a previous history of RCC prior to KTX were limited. A prior study demonstrated an incidence of
recurrent RCC after KTX of 9.1% with an associated 5-year survival of 41.7% [23]. Sensitivity analysis,
excluding the study of recurrent RCC among KTx recipients with a previous history of RCC prior to
KTX (23), demonstrated a pooled estimated mortality rate of 11.5% in KTx recipients with RCC (95%
CI: 6.4–19.8%, I2 = 67%).
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Figure 5. Forest plots of the included studies [13,14,16,17,19,20,23,30,33,36,39] assessing mortality rate
in KTx recipients with RCC. A diamond data marker represents the overall rate from each included
study (square data marker) and 95% confidence interval.
Meta-regression showed no significant correlations between the year of study and mortality of
patients with RCC (p = 0.50, Figure 6). When meta-regression was performed excluding the study of
recurrent RCC among KTx recipients with a previous history of RCC prior to KTX [30], there were still
no significant correlations between the year of study and mortality of patients with RCC (p = 0.56,
Figure 7).
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Figure 6. Meta-regression analyses showed no significant correlations between the year of study and
mortality of patients with RCC (p = 0.50). The solid line represents the weighted regression line based
on variance-weighted least-squares. The inner an outer lines show the 95% confidence i terval an
predictio interval around the regression line. The circles indicate the log event rates in each study.
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Figure 7. Meta-regression analyses, excluding the study of recurrent RCC among KTx recipients with a
previous history of RCC prior to KTX, showed no significant correlations between the year of study
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based on variance-weighted least-squares. The inner and outer lines show the 95% confidence interval
and prediction interval around the regression line. The circles indicate log event rates in each study.
3.3. Evaluation for Publication Bias
Funnel plots (Supplementary Figures S1 and S2) and Egger’s regression asymmetry tests were
performed to evaluate ublication bias in the analysis evaluating the incidence and mortality of
KTx recipients with RCC. There was o sig ificant publication bias, with p-values of 0.58 and
0.54, respectively.
4. Discussion
In this systematic review, we found that RCC after KTx occurs with an incidence of 0.7%. RCC
can occur in the native kidn y with an incidence of 0.7% or in the allograft kidney with an incidence of
0.2%. Our findings also showed a statistically significant negative correlation between e i cidence of
RCC after KTx a study year, representing a potential decrease in the RCC incidence among KTx
pat ents. However, mortality in KTx pati nts with RCC has n t decreas d over time.
Post-KTx malignancy is a common cause of death [5,6,47–51] and RCC is th most co mon
solid- rgan maligna cy in this p pulation [52,53]. Due to the incre sed risk of RCC among ESRD
patients [7,8], the Cli ical Practice G ideli es Committee f t AST has suggested R C screening in
ESRD patients on d alysis for longer than 3 years [9,10]. In addition, it is sugg sted that most KTx
candidates with a history o RCC should wait at least 2 years from successful cancer treatment to
(u less candidates have only small localized incidental tumors, which may not r quire any waiting
period) [54,55]. Candidates with large, invasive or symptomatic RCC ay require a longer
of 5 years [54,55]. Desp e RCC screening prior to KTx, the findings from ou study suggest hat
RCC can still occur post-KTx at a higher incidence (0.7%) than its reported incidence among ESRD
patients (0.3%) [8]. In additi n, studies have d monstrated that KTx recipients have a relative increased
risk of fiv - o ten-fold for RCC c mpared with an age-matched general population, and that th
majority of these tumors arise in the setting of acquired kidney cystic disease (AKCD) which develops
with chronic renal failure [5,8,35,56–64]. Although RCC occurrence is more frequ nt in the nat ve
kidneys of KTx recip ents, RCC can also occur in the renal allograft (incidence of 0.2%) [17,19,20].
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While the exact etiology of the increased risk of RCC in KTx remains unclear, it is likely
linked to the immunosuppressed state [4]. Reported risk factors for post-KTx RCC include older
age, male sex, African descent, excess body weight, smoking, hypertension, history of acquired
cystic kidney disease (ACKD), previous RCC prior to KTx, and longer pre-transplant dialysis
duration [3,6,18,23,29,31,34,35,65–67]. Studies have shown that causes of ESRD before KTx may
also affect the incidence of post-KTx RCC [14,32,35]. While KTx recipients with ESRD due to
glomerulonephritis, hypertensive nephrosclerosis, and vascular diseases have been shown to have a
higher incidence of post-KTx RCC, recipients with ESRD due to diabetic nephropathy carry a lower risk
of post-KTx RCC [14,32,35,68]. KTx recipients are usually under intensified medical surveillance and
the higher incidence of RCC among KTx recipients compared to general populations and ESRD patients
might be due to detection bias. On the other hand, the lack of consensual RCC screening among
KTx recipients may also have underestimated the exact incidence among the KTx patient population.
Currently, there are no universal recommendations for RCC screening among KTx patients [3,22,69–72].
While the European Renal Best Practice (ERBP) guidelines recommend native kidney ultrasound
as RCC screening in kidney transplant recipients, and the European Association of Urology (EAU)
recommends an annual ultrasound of native kidneys and allografts for anyone with ACKD, previous
RCC, or von Hippel–Lindau disease [3,71,72], the Kidney Disease Improving Global Outcomes (KDIGO)
and AST guidelines for post-KTx care currently do not suggest universal screening for RCC among KTx
recipients [22,69,70]. Thus, there are various RCC screening approaches for KTx recipients at different
transplant centers. Many cases of RCC have been discovered during investigations for post-transplant
erythrocytosis, elevated serum creatinine, hematuria, urinary infection, or incidentally from imaging
for other indications [33,73–75]. The majority of studies with available data on surveillance programs
performed screening for RCC post-KTx annually by ultrasonography of native and allograft kidneys.
Among KTx recipients with ACKD, acquired multicystic dysplasia, or a prior history of RCC required
more frequent screenings, every 6 months [16,17,19,20,28,36,76]. Given that the risk is greatest in
the first year post-KTx and the majority of RCCs occur in the first 5 years after KTx [15,29,31,65,77],
previous reports suggest that KTx recipients should routinely undergo ultrasonography to screen RCC
on the native kidney during the first 30 days post-KTx and every 5 years afterwards in the absence of
renal cysts, or every 2 years in the presence of renal cysts [65,77–79]. Our study’s findings suggest the
need for future studies to identify a cost-effective surveillance strategy for RCC among KTx recipients.
This strategy would need to take into consideration both native and allograft kidneys, and differentiate
KTx recipients with non-simple renal cysts [3,80].
Several limitations of our systematic review are worth mentioning. First, there are statistical
heterogeneities in our meta-analysis. Potential sources for heterogeneities were the variations
in the renal transplant recipient screening methods, patient characteristics, and differences in the
immunosuppressive regimens used at various transplant centers, which may have affected the incidence
of RCC and mortality rate in this population. Second, there is a lack of data from included studies
on immunosuppressive regimens [81–85]. Mammalian target of rapamycin (mTOR) inhibitors have
shown antineoplastic activities [86]. Although the effects of mTOR among KTx recipients have been
shown mostly for non-melanoma skin cancer [87–89], future studies evaluating the effects of different
immunosuppressive regimens on mortality in KTx patients with RCC are needed. Lastly, this is a
meta-analysis of cohort studies and the data from population-based studies were limited. Thus, large
population-based studies evaluating the incidence of RCC in KTx patients are required in the future.
In summary, the overall estimated incidence of RCC after KTX was 0.6%, with an associated
high mortality rate in KTx recipients of 13.9%. Despite potential improvements in the post-KTx RCC
incidence, the mortality in KTx patients with RCC has remained unchanged over time.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/4/530/s1,
Data S1: Search terms for systematic review; Figure S1: Funnel plot evaluating for publication bias evaluating
incidence of KTx recipients with RCC; Figure S2: Funnel plot evaluating for publication bias evaluating mortality
of KTx recipients with RCC.
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